Merck & Co Inc (Kenilworth, NJ) purchased cCam Biotherapeutics (Misgav, Israel) for $605 million. cCam is an oncology company focused on developing cancer immunotherapies such as its lead product CM-24, a monoclonal antibody that targets a protein, which may treat advanced malignant cancers. Terms of the agreement include a $95 million cash payment from Merck to cCam and an additional $510 million to shareholders. There were no additional details on the expected completion date of the deal.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.